ACHE and early-onset autosomal dominant Alzheimer disease: Collectively, our findings established that compound 5b is a potent, selective and competitive inhibitor of acetylcholinesterase and can serve as a promising candidate for further preclinical development for the therapy of Alzheimer’s disease.